Haleon · 6 hours ago
2026 Intern: Product Development - OTC (12 weeks, June 2026 start)
Haleon is a world-leading consumer healthcare company dedicated to delivering better everyday health with humanity. They are seeking an intern in product development to support new product development as part of the US Respiratory R&D team, working closely with a technical mentor and conducting lab experiments.
ConsumerHealth CareMedical
Responsibilities
Support new product development as an integrated member of the US Respiratory R&D team
Work in close partnership with a technical mentor
Support fellow team members in conducting lab experiments, developing formulations and/or providing analysis and evaluation of material and products at all stages of the development process
Qualification
Required
Pursuing a BS degree in Chemical, Pharmaceutical, or related science
Must have an active student status. Post-doctoral candidates are not eligible
Candidate must be able to work full-time (40 hours/ week) Monday-Friday for 12 weeks
Ability to start in June 1st, 2026
This role is onsite at our Richmond, VA location
Provide your own funding for relocation and commuting
Must be eligible to work in the US at the time of, and for the duration of employment. Employees will be required to furnish evidence of US work authorization
Creative and problem-solving thinking
Strategic/big-picture thinking
Entrepreneurial and agile mindset
Strong prioritisation and analytical skills
Personal accountability
Business and consumer/customer knowledge and understanding
Adaptability and resilience in ambiguity
A desire to learn and have meaningful impact
Curiosity and eagerness to learn
Preferred
Hands on lab experience and experience maintaining an accurate laboratory notebook
Basic knowledge of scientific principles and techniques
Awareness of safe laboratory practices, PPE requirements, hazardous waste handling and disposal
Company
Haleon
Haleon is to deliver better everyday health with humanity.
Funding
Current Stage
Public CompanyTotal Funding
$3.06B2025-01-16Post Ipo Secondary· $3.06B
2022-07-18IPO
Recent News
2026-01-11
2026-01-11
Company data provided by crunchbase